Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying


Industry analysts insist that the new diabetes and weight loss drugs, such as Ozempic, won’t affect demand for continuous glucose monitors and insulin pumps. But most investors don’t buy it. UBS analyst Danielle Antalffy lowered her price targets on Wednesday for Dexcom, and several small-to mid-cap names. She believes that historical valuation multiples for this group have decreased for the near future. She wrote that current multiples “seem to be pricing an overly-bearish view”, in which